Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs S&P Global Inc (SPGI) Price & Performance

BridgeBio Pharma IncTrade
S&P Global IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs S&P Global Inc — how do they compare? BridgeBio Pharma Inc trades at $83.41 (market cap $16.36B), while S&P Global Inc trades at $409.5 (market cap $120.48B). The key difference: S&P Global Inc is far larger — about 7.4× BridgeBio Pharma Inc's market cap, and S&P Global Inc pays a 0.95% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOSPGI
Market Cap
$16.36B$120.48B
Sector
HealthFinancials
52-Week High
$90.17$534.79
52-Week Low
$47.29$370.42
Enterprise Value
$18.14B$131.97B
Dividend Yield
0.95%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About S&P Global Inc

S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.

Read more on SPGI